N+1 Singer reiterated their buy rating on shares of Cello Group plc (LON:CLL) in a report released on Tuesday morning. They currently have a GBX 128 ($1.67) target price on the stock, up from their previous target price of GBX 127 ($1.66).

A number of other equities analysts have also weighed in on the company. Peel Hunt reiterated a buy rating on shares of Cello Group plc in a research note on Wednesday, July 13th. Cenkos Securities Ltd reissued a buy rating on shares of Cello Group plc in a research report on Wednesday, September 14th.

Cello Group plc (LON:CLL) opened at 108.71999 on Tuesday. The firm has a 50-day moving average price of GBX 104.12 and a 200 day moving average price of GBX 97.73. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00. The company’s market cap is GBX 94.38 million.

The business also recently declared a dividend, which will be paid on Friday, November 4th. Investors of record on Thursday, October 6th will be given a dividend of GBX 1 ($0.01) per share. This represents a yield of 0.94%. The ex-dividend date of this dividend is Thursday, October 6th.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.